Key result
Aspirin therapy (150-200 mg/day) did not show superiority over no treatment for preventing cardiovascular death, brain infarction, or TIA in NVAF patients (3.1% vs 2.4% per year).
Why the study?
Does aspirin 150 to 200 mg per day reduce cardiovascular death, symptomatic brain infarction, or transient ischemic attack in Japanese patients with nonvalvular atrial fibrillation?
Population
871 Japanese patients with nonvalvular atrial fibrillation (NVAF)
Comparison
Aspirin 150 to 200 mg per day vs Control group without antiplatelet or…
Design
RCT, Randomized
Authors
Loading...
Aspirin should not be used for primary stroke prevention in NVAF; confirms no benefit over no treatment in this RCT.
RCT (n=871)
Yes
Does aspirin 150 to 200 mg per day reduce cardiovascular death, symptomatic brain infarction, or transient ischemic attack in Japanese patients with nonvalvular atrial fibrillation?
Absolute Event Rate: 3.1% vs 2.4%
Aspirin at 150 to 200 mg per day is neither effective nor safe for the primary prevention of stroke in Japanese patients with nonvalvular atrial fibrillation.
Sato et al. (2005) conducted an RCT in Nonvalvular atrial fibrillation (NVAF) (n=871). Aspirin vs. No antiplatelet or anticoagulant therapy was evaluated on Cardiovascular death, symptomatic brain infarction, or transient ischemic attack. Aspirin therapy (150-200 mg/day) did not show superiority over no treatment for preventing cardiovascular death, brain infarction, or TIA in NVAF patients (3.1% vs 2.4% per year).